CD BioSciences is a biotechnology company focused on providing services related to life sciences, especially in the field of 3D bioprinting. Our proprietary high-resolution 3D printing technology platform called 3Dmicroflu™ can be involved in the construction of various in vitro disease micro-models that fully reflect physiological characteristics. These disease micro-models can assist you in your in vitro disease mechanism research and related drug development efforts.
Disease is an abnormal process of life activity caused by the disruption of the body's self-regulation of stability under the action of certain etiological factors. In this process, the organism enters a state of imbalance in the internal environment homeostasis and incompatibility with the environment. The mechanisms of disease occurrence are intricate and complex, and the research process is generally very long and uncomplicated. However, the study of disease mechanisms is very meaningful and is the basis for subsequent drug development. Only when the mechanisms of disease occurrence are understood, then drug development will be targeted. The mechanism and principle of action of drugs are based on the mechanism of disease occurrence, and drugs can generally produce effects by blocking the occurrence of diseases. Therefore, the study of the mechanism of the disease is fundamental to the research of the treatment method of the disease.
Disease models are an important part of the disease mechanism research process and are a decisive factor in determining the speed of the research process. Here, CD BioSciences can provide you with a range of services for building disease models based on high-resolution 3D bioprinting 3Dmicroflu™ technology platform to assist you in the process of disease mechanism research more conveniently.
3Dmicroflu™ is CD BioSciences' proprietary 3D printing technology platform that offers significant advantages in the in vitro construction of various disease micro-models. The design and customization of a range of disease micro-models based on the 3Dmicroflu™ technology platform can greatly facilitate your experimental projects on disease mechanisms, mainly for some of the following common disease types.
The study of tumour pathogenesis and treatment has been a key field of interest for researchers. 3Dmicroflu™ technology platform can be applied to the in vitro construction of a range of disease models that can better match the tumour microenvironment. It is of great significance for studying the complex mechanisms of tumour diseases.
The study of the pathogenesis of cardiovascular diseases and the development of therapeutic drugs are still hot spots that need breakthroughs. First of all, the construction of cardiovascular disease models is the fundamental issue that determines the subsequent research of cardiovascular diseases. CD BioSciences is always committed to provide you with 3Dmicroflu™-based in vitro cardiovascular disease micro-models.
CD BioSciences can provide you with the 3Dmicroflu™ technology platform to assist you in constructing fibrotic disease models and conducting research related to fibrotic disease mechanisms. Once fibrosis occurs, the damage is irreversible. Therefore, it is very important to study the pathogenesis of fibrosis and develop appropriate methods to prevent and treat it.
Skin models have always been an important component of in vitro testing in the study of dermatopathogenesis. CD BioSciences offers a high resolution 3D printing technology platform called 3Dmicroflu™ for the personalized design and construction of skin models. The ability to construct models in vitro that realistically reproduce the skin features of the physiological environment will greatly facilitate the process of dermatological research.
At CD BioSciences, we offer you a high-resolution 3D bioprinting 3Dmicroflu™ technology platform for constructing models to study the mechanisms of neurological diseases. Our experienced team of experts can design and customize models for different neurological diseases by using 3Dmicroflu™ technology platform for high precision and high resolution 3D printing.
CD BioSciences has 3Dmicroflu™ technology platform that enables the 3D printing of high-resolution and structurally complex in vitro models of immune system diseases. Using patient cells to print personalized in vitro micro-models through 3Dmicroflu™ technology platform allows for personalized drug screening, which is consistent with precision therapy.
Metabolism is the basis of life activities and is the causative agent of many diseases. The study of its mechanisms is an important part of basic biology research. CD BioSciences offers 3Dmicroflu™ technology platform for high-resolution 3D printing of organ micro-models for studies of organ metabolic mechanisms, related diseases and toxicity testing in drug development.
CD BioSciences offers 3Dmicroflu™, a high-resolution 3D bioprinting technology platform that can be applied to the construction of skeletal disease models for mechanistic studies and related drug development. 3Dmicroflu™ is a microfluidic system-based 3D printing technology platform that enables the construction of complex and detailed structures in vitro through high-resolution single-cell printing.
CD BioSciences offers a high-resolution 3D bioprinting 3Dmicroflu™ technology platform with applications for constructing in vitro infection models to screen for specific infectious disease drugs. Prevention is an important way to control infectious diseases, but treatment of infectious diseases is also important. The construction of in vitro infection models for infectious diseases can guide the development of relevant drugs and therapies.
When you have cosmetics industry quality assessment needs or any type of in vitro disease micro-model construction needs, our high resolution 3Dmicroflu™ technology platform will be the best choice for you. If you are interested in 3Dmicroflu™-based micro-models or if your experimental project requires custom models, please feel free to contact us for custom services. All services are available on a 24/7/365 basis.